| abstract |
FIELD: pharmacology. n SUBSTANCE: invention relates to compounds of the general formula (I) n , n where R 1 and R 2 are different or identical and are independently selected from the group consisting of: - H; -(C 1 -C 6 )haloalkyl; -(C 1 -C 6 )alkyl optionally substituted by one or more substituents selected from (C 3 -C 7 )cycloalkyl; and -(C 3 -C 7 )cycloalkyl; A is a monocyclic heteroaryl ring system selected from the group consisting of radicals n , , , and , n n is 0, 1 or 2; R 3 is a possible substituent, which in each case is selected from the group consisting of: -(C 1 -C 6 )alkyl, optionally substituted by (C 3 -C 7 )cycloalkyl; -OR 4 , (the meaning of the remaining radicals is given in claim 1), its corresponding N-oxide over the pyridine ring and pharmaceutically acceptable salts or solvates thereof. The compounds obtained are inhibitors of the phosphodiesterase 4 (PDE4) enzyme. n EFFECT: increased efficiency. n 14 cl, 8 tbl, 19 ex |